Generex Biotechnology Corp (GNBT) financial statements (2022 and earlier)

Company profile

Business Address 10102 USA TODAY WAY
MIRAMAR, FL 33025
State of Incorp. DE
Fiscal Year End July 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in thousands)

4/30/2021
Q3
1/31/2021
Q2
10/31/2020
Q1
7/31/2020
Q4
4/30/2020
Q3
1/31/2020
Q2
10/31/2019
Q1
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments1,67559683415417269540
Cash and cash equivalents1,67559683415417269540
Inventory, net of allowances, customer advances and progress billings232618719742911861727
Inventory232618719742911861727
Other current assets509389307332624504451
Other undisclosed current assets52169184165142240155
Total current assets:2,4691,7732,0431,2552,0931,8741,873
Noncurrent Assets
Operating lease, right-of-use asset157178223813916698
Property, plant and equipment116145176214245483532
Intangible assets, net (including goodwill)36,86037,09037,32137,55238,90140,78740,943
Goodwill34,48934,48934,48934,48938,90138,90138,901
Intangible assets, net (excluding goodwill)2,3712,6002,8323,063 1,8862,041
Other undisclosed noncurrent assets6,3216,3246,3246,32410,5178,7938,795
Total noncurrent assets:43,45443,73743,84244,12849,80250,22950,367
TOTAL ASSETS:45,92345,51045,88545,38351,89552,10352,240
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities, including:40,96139,31733,46423,90821,53724,11822,448
Accounts payable   1,316   
Employee-related liabilities7,0607,0607,005    
Interest and dividends payable   3,911   
Other undisclosed accounts payable and accrued liabilities33,90132,25726,45918,68121,53724,11822,448
Deferred revenue7,0003,000     
Debt8,56310,0579,98111,16612,14511,9071,026
Derivative instruments and hedges, liabilities   1,317   
Due to related parties153030    
Other undisclosed current liabilities7,5357,2818,9684,9816,0311,53210,788
Total current liabilities:64,07459,68552,44341,37139,71337,55634,262
Noncurrent Liabilities
Long-term debt and lease obligation6546155005005607322
Long-term debt, excluding current maturities552499500500499  
Operating lease, liability102116  607322
Liabilities, other than long-term debt16,77431,75016,4931,31710,32010,3628,797
Derivative instruments and hedges, liabilities16,77431,75016,4931,31710,32010,3628,797
Other undisclosed noncurrent liabilities8,5048,5728,48310,07918788216
Total noncurrent liabilities:25,93240,93725,47611,89611,06710,5239,035
Total liabilities:90,007100,62377,91853,26750,78048,08043,297
Temporary equity, carrying amount4,0744,0744,0744,0744,0744,0744,074
Stockholders' equity
Stockholders' equity attributable to parent, including:(48,157)(59,187)(36,107)(11,958)(2,959)(51)4,869
Common stock11611310882806944
Common stock, share subscribed but unissued, subscriptions receivable    (768)(768) 
Additional paid in capital422,298420,021418,411429,744427,623420,206417,082
Accumulated other comprehensive income754766778780792775797
Accumulated deficit(479,502)(488,724)(464,644)(452,063)(440,390)(434,763)(427,854)
Stockholders' equity note, subscriptions receivable (275)     
Other undisclosed stockholders' equity attributable to parent8,1768,9139,2399,4989,70314,43014,800
Total stockholders' equity:(48,157)(59,187)(36,107)(11,958)(2,959)(51)4,869
TOTAL LIABILITIES AND EQUITY:45,92345,51045,88545,38351,89552,10352,240

Income statement (P&L) ($ in thousands)

4/30/2021
Q3
1/31/2021
Q2
10/31/2020
Q1
7/31/2020
Q4
4/30/2020
Q3
1/31/2020
Q2
10/31/2019
Q1
Revenues21 88(2,078)499857722
Cost of revenue(66)(105)(23)(164)(116)(166)(134)
Other undisclosed gross profit   2,661   
Gross profit:(45)(105)65419382692588
Operating expenses(6,318)(8,472)(14,178)(5,675)(3,957)(5,250)(5,317)
Other undisclosed operating income (loss)  (0)   180
Operating loss:(6,363)(8,577)(14,113)(5,256)(3,574)(4,558)(4,549)
Interest and debt expense(1,052)(587)(1,019)(1,650)(1,506)(1,431)(2,919)
Loss before gain (loss) on sale of properties:(7,415)(9,164)(15,132)(6,906)(5,080)(5,989)(7,468)
Other undisclosed net income15,900      
Net income (loss):8,485(9,164)(15,132)(6,906)(5,080)(5,989)(7,468)
Net income attributable to noncontrolling interest737326258206134371187
Other undisclosed net income (loss) attributable to parent(737)(15,569)3,885(5,178)(815)(1,661)(2,031)
Net income (loss) attributable to parent:8,485(24,407)(10,989)(11,879)(5,761)(7,280)(9,313)
Other undisclosed net income available to common stockholders, basic737326258206134371187
Net income (loss) available to common stockholders, basic:9,223(24,081)(10,731)(11,673)(5,626)(6,910)(9,126)
Dilutive securities, effect on basic earnings per share25,802      
Other undisclosed net loss available to common stockholders, diluted(41,165)      
Net loss available to common stockholders, diluted:(6,140)(24,081)(10,731)(11,673)(5,626)(6,910)(9,126)

Comprehensive Income ($ in thousands)

4/30/2021
Q3
1/31/2021
Q2
10/31/2020
Q1
7/31/2020
Q4
4/30/2020
Q3
1/31/2020
Q2
10/31/2019
Q1
Net income (loss):8,485(9,164)(15,132)(6,906)(5,080)(5,989)(7,468)
Comprehensive income (loss):8,485(9,164)(15,132)(6,906)(5,080)(5,989)(7,468)
Comprehensive income, net of tax, attributable to noncontrolling interest737326258206134371187
Comprehensive income (loss), net of tax, attributable to parent:9,223(8,838)(14,874)(6,701)(4,946)(5,619)(7,281)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: